Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine for treating chronic hepatitis B virus infection

A technology for hepatitis B virus and hepatitis B, applied in antiviral agents, drug combinations, pharmaceutical formulas, etc., to achieve non-immunogenicity, safe and convenient use, and reduce liver lymphocyte infiltration

Inactive Publication Date: 2015-05-20
CHINA AGRI UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The current recombinant hepatitis B vaccine can make 90% of the vaccinators produce protective antibodies; but for chronic HBV carriers, because the body is resistant to HBsAg protein, it cannot stimulate the body to produce humoral and cellular immunity, so it can only be used as a preventive vaccine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for treating chronic hepatitis B virus infection
  • Medicine for treating chronic hepatitis B virus infection
  • Medicine for treating chronic hepatitis B virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0072] Example 1, Purification of Pleurotus lectin

[0073] 1. After the fruiting bodies of Pleurotus pachyrhiza are mashed, the fruiting bodies of Pleurotus pachyrhiza are obtained, and 750 grams of Pleurotus pleurotus fruiting body powder are prepared by using 2000 milliliters of 0.15mM NaCl aqueous solution at 4°C (0.1-0.2mM NaCl aqueous solution at 0-4°C) Both) were extracted for 2-12 hours, and the supernatant was taken after centrifugation. (The ratio of the fruiting bodies of Pleurotus chinensis to the aqueous solution of NaCl is 500-750 grams: 2000 milliliters is acceptable)

[0074] 2. The supernatant was washed with 80% saturation (NH 4 ) 2 SO 4 The aqueous solution (30%-80% saturation is acceptable) is precipitated for 6 hours (4-8 hours are acceptable), and the precipitate is collected after centrifugation.

[0075] 3. Dissolving the precipitate with PBS and then dialysis to obtain a crude sample of Pleurotus agglutinin.

[0076] 4. The crude sample of Pleurot...

Embodiment 2

[0083] Example 2. Effect of Pleurotus agglutinin on the Effect of Recombinant Hepatitis B Vaccine in Treating Hepatitis B Virus Infection

[0084] 1. Detection of immunogenicity and side effects of Pleurotus agglutinin

[0085] (1) Immunization

[0086] Twenty female C57BL / 6 mice were randomly divided into 2 groups, 10 in each group, and were treated as follows:

[0087] Control group: Each mouse was injected with 100 microliters of normal saline as a control.

[0088] Immunization group: each mouse was injected with 1 microgram of Pleurotus agglutinin prepared in Example 1 dissolved in physiological saline in 100 microliters.

[0089] The mice in each of the above groups were immunized by intramuscular injection for a total of 3 times, with an interval of 2 weeks between each immunization, and the immunization time points were consistent.

[0090] (2) Detection of Pleurotus agglutinin-specific antibody

[0091] On the 7th day after the last immunization, blood was taken fro...

Embodiment 3

[0159] Example 3. Comparison of therapeutic effects of Pleurotus agglutinin and HBV DNA vaccine synergy and Pleurotus agglutinin and recombinant hepatitis B vaccine on HBsAg transgenic mice

[0160] 1. Immunity

[0161] Twenty HBsAg transgenic mice were randomly divided into 4 groups, with 5 mice in each group, and were treated as follows:

[0162] 1) Model group: each transgenic mouse was injected with 100 microliters of normal saline as a control;

[0163] 2) Pleurotus agglutinin combined with HBV DNA vaccine group: 100 micrograms of proVAX-S2 plasmid and 1 microgram of Pleurotus agglutinin prepared in Example 1 were added to 100 microliters of normal saline to make an immune reagent, and each mouse was injected 100 μl of the immunological reagent.

[0164] 3) Pleurotus agglutinin synergistically with recombinant hepatitis B vaccine group: add 1 microgram of Pleurotus agglutinin prepared in Example 1 to 100 microliters of recombinant hepatitis B vaccine (containing 2 micro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicine for treating chronic hepatitis B virus infection. The invention discloses an application of pleurotus ostreatus lectin in preparing an antiviral drug adjuvant. The invention proves that the pleurotus ostreatus lectin can significantly improve the effect of a recombinant hepatitis B vaccine on treating chronic hepatitis B virus infection; and the medicine disclosed by the invention has an application prospect in the field of treating hepatitis B.

Description

technical field [0001] The invention relates to a medicine for treating hepatitis B virus infection, in particular to a medicine for treating chronic hepatitis B virus infection, and belongs to the field of biotechnology. Background technique [0002] Hepatitis B (Hepatitis B, HB) is an important infectious disease caused by hepatitis B virus (Hepatitis B virus, HBV), which seriously endangers human health. Chronic hepatitis caused by hepatitis B virus infection is a global public health problem, which brings huge economic burden to patients and society. Persistent HBV infection can cause the body to develop immune tolerance against HBV antigens, leading to chronic HBV infection. HBV infection causes the virus to persist in the host and the key to the chronicity of the disease process is that the body lacks an effective immune response and cannot clear the virus. At present, chronic HBV infection mainly relies on nucleoside analogues and interferon for treatment, which hav...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61K39/29A61P1/16A61P31/20A61K38/36
Inventor 康友敏刘庆洪康敬敬
Owner CHINA AGRI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com